Peer-influenced content. Sources you trust. No registration required. This is HCN.

myCMEWhere do Anti-TROP2 ADCs Factor into Advanced TNBC Care?

Unfolding the Potentials of Anti-TROP2 ADC Therapy in Triple-Negative Breast Cancer

Evolving therapeutic paradigms for triple-negative breast cancer (TNBC) are in focus, as esteemed experts highlight the use of novel anti-TROP2 antibody drug conjugates in an enlightening multidisciplinary tumor board.

  • Educational activity exploring innovative treatment approaches for TNBC, requiring 30 minutes to complete.
  • Focuses on a patient with advanced TNBC, assessing the potential role of anti-TROP2 ADCs therapy.
  • Aimed at medical oncologists, surgical oncologists, oncology nurses, and healthcare providers involved in TNBC care.
  • Funded by an educational grant from Gilead Sciences, Inc.
  • Objectives include discussing targeted treatments and ADC therapies’ role, particularly TROP2, in TNBC context.
  • Faculty disclosures reveal affiliations with various pharmaceutical companies; all conflicts of interest have been addressed.
  • The program expires on August 3, 2023, offering 0.50 AMA PRA Category 1 Credits™.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form